But the incumbents look set to fight to hold on to the market, with Alnylam Pharmaceuticals sharing early-phase data on its ...

Analysts appear optimistic for Intellia’s gene editor nex-z, which showed a greater serum TTR reduction than Alnylam’s ...

Intellia Therapeutics CEO John Leonard has, for the last couple years, found himself stuck in a financial Groundhog Day.

Intellia's Phase 3 trial for NTLA-2002 shows promise, but limitations warrant caution. See why we believe NTLA stock is hold ...

Phase 1 data indicate Intellia’s medicine could be a powerful treatment for a cardiac form of ATTR amyloidosis. But rival drugs are further ahead.

Intellia Therapeutics ( (NTLA) ) just unveiled an announcement.Don't Miss our Black Friday Offers:Discover the latest stocks recommended by top ...

In one of the most close­ly-watched are­nas in biotech, In­tel­lia says its gene edit­ing treat­ment for a heart mus­cle ...

Terence Flynn has given his Buy rating due to a combination of factors that highlight Intellia Therapeutics’ promising clinical data and competitive positioning in the market. The recent updates from ...

A CRISPR-Cas9-based investigational therapy was linked with a drop in serum transthyretin (TTR) levels in patients with ...

For reference, the recently approved CRISPR drug Casgevy costs $2.2 million for a course of treatment. Therefore, any ...

Intellia Therapeutics reported better-than-expected third-quarter earnings, highlighting advancements in its CRISPR ...

Intellia tried to allay some of those concerns on Saturday with new year-long data from the 36 patients treated in an early trial of its CRISPR drug for ATTR cardiomyopathy.